Individuals infected with human immunodeficiency virus (HIV) have excess risk of
developing human papillomavirus (HPV)-related disease. A substantial fraction of HPV …

Ninety-one HIV-infected individuals (61 men and 30 women) were randomized to
vaccination either with quadrivalent (Gardasil™) or bivalent (Cervarix™) HPV vaccine …

Protection against oncogenic non-vaccine types (cross-protection) offered by human
papillomavirus (HPV) vaccines may provide a significant medical benefit. Available clinical …

Background. We compared the immunogenicity and reactogenicity of Cervarix or Gardasil
human papillomavirus (HPV) vaccines in adults infected with the human immunodeficiency …

Human papillomavirus (HPV) infection is a frequent cause of malignant and non-malignant
disease, in particular among persons with HIV. HPV serotype-specific anti L1 antibodies …

This observer-blind study compared the prophylactic human papillomavirus (HPV) vaccines,
Cervarix™(GlaxoSmithKline) and Gardasil®(Merck), by assessing immunogenicity and …

In this observer-blind study (NCT00423046), women (N= 1,106), stratified by age (18–26, 27–
35, 36–45 years), were randomized (1: 1) to receive the HPV-16/18 vaccine (Cervarix® …

Two HPV virus-like particle (VLP) vaccines, HPV-16/18 (GlaxoSmithKline, Cervarix®) and
HPV-6/11/16/18 (Merck, Gardasil®), are currently licensed in the United States. Given the …

Persons with HIV are at increased risk of HPV infection, HPV disease, and HPV-related
cancers compared to HIV negative persons. In persons with HIV, immune responses to …

BACKGROUND: We previously demonstrated that Cervarix® elicits antibody responses
against vaccine-related types for which clinical efficacy was demonstrated (HPV-31 and-45) …